The Company's business operations are not affected by the Nasdaq notification letter. The Company intends to monitor the closing bid price of its ADSs between now and April 26, 2023 and will take all reasonable measures in order to regain compliance with the Nasdaq minimum bid price requirement. About Genetron Holdings Limited Genetron Holdings Limited ("Genetron Health" or the "Company") GTH is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.